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Background/aim: In children with autosomal dominant polycystic kidney disease (ADPKD), clinical manifestations range from severe
neonatal presentation to renal cysts found by chance. We aimed to evaluate demographic, clinical, laboratory findings, and genetic
analysis of children with ADPKD.
Materials and methods: We evaluated children diagnosed with ADPKD between January 2006 and January 2019. The diagnosis was
established by family history, ultrasound findings, and/or genetic analysis. The demographic, clinical, and laboratory findings were
evaluated retrospectively. Patients <10 years and ≥10 years at the time of diagnosis were divided into 2 groups and parameters were
compared between the groups.
Results: There were 41 children (M/F: 18/23) diagnosed with ADPKD. The mean age at diagnosis was 7.2 ± 5.1 (0.6–16.9) years and
the follow-up duration was 59.34 ± 40.56 (8–198) months. Five patients (12%) were diagnosed as very early onset ADPKD. All patients
had a positive family history. Genetic analysis was performed in 29 patients (PKD1 mutations in 21, PKD2 mutations in 1, no mutation
in 3). Cysts were bilateral in 35 (85%) of the patients. Only one patient had hepatic cysts. No valvular defect was defined in 12 patients
detected. Only 1 patient had hypertension. None of them had chronic kidney disease. No difference could be demonstrated in sex,
laterality of the cysts, maximum cyst diameter, cyst or kidney enlargement, follow-up duration, or GFR at last visit between Groups 1
and 2.
Conclusion: The majority of children with ADPKD had preserved renal functions and slight cyst enlargement during their follow-up.
However, they may have different renal problems deserving closed follow-up.
Key words: Autosomal dominant polycystic kidney disease, children

1. Introduction
Autosomal dominant polycystic kidney disease (ADPKD,
previously termed adult polycystic kidney disease) is
the most common hereditary renal disorder [1]. It is
characterized by cystic dilations generating from any
part of the nephron with enlarged kidneys and occurs
in 1:1000 live births [1,2]. The disease is genetically
heterogeneous and the genes involved are PKD1, located
on chromosome 16p13.3, and PKD2, located on 4q21,
encoding polycystin-1 and -2, respectively [1,2].
Most patients with ADPKD present as adults; however,
the timing of cyst generation may be discrete leading to
the antenatal period. Cysts enlarge by age. Cyst burden
may be significant in childhood and renal failure typically
develops in the sixth decade [1]. Why some cases of

ADPKD present in childhood is unclear, because there is
no evidence for genetic heterogeneity [2]. Screening and
monitoring is controversial in the childhood [2].
Polyuria/polydipsia is usually the first biological
renal manifestation, which is associated with decreased
concentrating ability [1,2]. Other renal manifestations
include flank pain, hematuria, proteinuria, hypertension,
nephrolithiasis, urinary tract infections, infection of
the cysts, or hemorrhagia into the cysts [1–3]. It is a
systemic disorder and extrarenal manifestations including
hepatic, pancreatic or seminal vesicle cysts, cerebral
aneurysms, aortic aneurysms and dissection, coronary
artery aneurysms, colonic diverticula, abdominal wall
and inguinal hernia and cardiac valve disease may occur
[1,2]. Although they are well-defined in adults, diagnostic
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criteria and management consensus are uncertain in
children.
In this study, we evaluated demographic, clinical,
laboratory findings, and genetic analyses of our patients
with ADPKD. We aimed to report familial burden, genetic
contribution, cyst characteristics, renal and extrarenal
manifestations, treatment options and follow-up modalities
in a series of children being followed up in our clinic for
a relatively long period and demonstrated whether these
parameters differed between cases diagnosed in the first
decade or thereafter.
2. Materials and methods
We evaluated children diagnosed with ADPKD between
January 2006 and January 2019. The diagnosis was
established by family history, ultrasound findings, and/
or genetic analysis. The demographic, clinical, and
laboratory findings including age at diagnosis, sex, followup duration, parental inheritance pattern, the number
of people diagnosed with ADPKD in the family, renal
manifestations including laterality of cysts, number
and diameter of the largest cysts at first and last visit in
each kidney on ultrasound, extrarenal manifestations,
evidence for hypertension (HT), kidney stone, urinary
tract infections (UTIs), hematuria, proteinuria or pyuria,
GFR at the last visit and genetic mutations (if available)
were evaluated retrospectively. Children diagnosed in
utero or within the first 18 months of life were grouped
as very early onset (VEO) ADPKD [2]. Genetic analysis
has been performed by Sanger sequencing until a few years
ago. Only PKD1 mutation could have been defined by this
method. Then, next-generation sequencing went into use
for screening both PKD1, PKD2, and PKHD1 mutations.
Cyst enlargement per month (CEM) was estimated by
the formula: Δ cyst diameter (diameter of the largest cyst at
last visit – diameter of the largest cyst at first visit/followup duration). Kidney enlargement per month (KEM) has
been determined for both right and left kidneys by the
following equation: Δ kidney length (kidney length at
last visit – kidney length at first visit)/follow-up duration.
The highest KEM was recorded. Hypertension was
defined as blood pressure ≥95 percentile for height and
sex. Pyuria was defined as ≥5 white blood cells/mm3 and
microscopic hematuria was defined as ≥5 red blood cells/
mm3. Proteinuria was defined as a protein/creatinine ratio
>0.21 in the spot urine sample or ≥4/mg/m2/h in 24-h
collected urine. The estimated glomerular filtration rate
(eGFR) was calculated due to the Schwartz formula as
follows: eGFR = k x height in cm/serum creatinine. Since
the serum creatinine is determined by Jaffe’s reaction in
our laboratory, we used 0.55 for girls and boys younger
than 13 years and 0.7 for boys ≥13 years for constant k,
which is directly proportional to the muscle component.

Glomerular hyperfiltration (GHF) was defined as GFR
≥140 mL/min/1.73 m2 [4].
Patients were divided into 2 groups due to their age
at diagnosis arbitrarily. Patients <10 years at the time of
diagnosis were grouped as Group 1 to present patients
diagnosed in the first decade. Patients, those ≥10 years
were diagnosed as Group 2. The parameters described
above were compared between the groups.
Statistical analyses were performed using IBM SPSS
22.0 (IBM Corp., Armonk,NY, USA). Kolmogorov–
Smirnov test was used to evaluate the normal distribution
of continuous variables between the groups. The
continuous variables were presented as either mean ±
standard deviation or median (25p–75p) according to
data distribution and categorical variables were presented
as percentage. The parameters with normal distribution
were compared by Student’s t-test, whereas those without
normal distribution were evaluated by Mann–Whitney
U test. The categorical variables between the groups were
compared using the chi-square test. Depending on the
distribution type of the variables, Pearson or Spearman
correlation analysis was performed. A P value of <0.05 was
considered significant in all statistical evaluations.
3. Results
There were 41 children diagnosed with ADPKD in the
mentioned period. Of those patients, 18 (44%) were male
and 23 (56%) were female. The mean age at diagnosis was
7.2 ± 5.1 (0–16.9) years. Five patients (12%) were diagnosed
as VEO ADPKD. The mean follow-up duration was 59.34
± 40.56 (8–198) months. A family history of ADPKD
was known at admission in all patients. Inheritance was
maternal in 20 (49%) and paternal in 21 (51%) of them.
Twenty (49%) of the patients were siblings belonging to
9 families. The mean number of patients diagnosed with
ADPKD in the family were 4.33 ± 1.81 (1–7).
Genetic analysis could have been performed in 29
(70%) of the patients (Table 1). In 4 of them, PKD1
mutation was found by Sanger sequencing. In the rest of
the group detected by next-generation sequencing, no
mutation could be detected in 3 patients, while 1 had
PKD2 mutation and 21 had PKD1 mutation. Of the 5
VEO patients, 2 had in utero cysts and early diagnosis as
their parents had the disease and requested screening for
ADPKD. Of the latter two, one had a stop codon mutation,
while the other had a missense mutation (Table 2).
Renal cysts were bilateral in 35 (85%) of the patients.
The remaining three had cysts on the left and three had
cysts on the right kidney at the first visit and three of
them had bilateral cysts at last visit. The mean diameter
of the largest cyst at the last follow-up was 14.49 ± 9.5
(2–60) mm. The calculated CEM was 0.19 ± 0.2 (–0.13–
0.77) and KEM was 0.31 ± 0.13 (–0.15–0.54). Only one
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Table 1. Mutations in children with ADPKD.
Patients

Mutations

P1

p.L727P (c.2180T>C)

P2

Ala3281Thr (c.9841G>A)

P3-5 (F1)

p.Glu2771Lys (c.8311G>A)

P6-7 (F2)

p.Asp3451Asn(c.10351G>A)

P8-10 (F3)

p.Phe2979del (c.8935-8937delTTC)

P11

No mutation

P12

p.Val2334fs (c.7000_7001insGCTGGCG)

P13

p.Gly3144Ala(c.9431G>C)

P14

p.Arg325X (c.973C>T)*

P15-16 (F4)

p.Thr579Met (c.1736C>T) ( Heterozygous)

P17-18 (F5)

p.Pro2258Arg (c.6773C>G)(Heterozygous)

P19-20 (F6)

p.Leu1486fs (c.4454_4455insTA)

P21

3793GlyfsX3826

P22

Thr3510Met

P23-24 (F7)

3791SerfsX3814

P25

p.Glu3518X (c.10552 G>T)

P26

p.Glu2771Lys (c.8311 G>A)

P27

p.Arg4154Cys (c.12460 C>T)

P28

No mutation

P: patient, F: family, *: mutation in PKD2 gene.

patient had hepatic cysts, and none of them had splenic or
pancreatic cysts. Cranial magnetic resonance angiography
was performed in 5 patients and none had an aneurysm.
Echocardiography was performed in 12 of the patients that
were normal in 11 and demonstrated PFO in one of them.
Recurrent UTIs were detected in 6 (14%), HT was
observed in 1 (2%), urolithiasis was defined in 3 (7%),
proteinuria in 6 (15%), pyuria in 4 (10%), and hematuria
in 5 (12%) of the patients. None had chronic kidney
disease in the follow-up and mean GFR at the time of the
last visit was 127.3 ± 21.8 (89.8–172) mL/min/1.73m2.
No difference could be demonstrated in sex, laterality of
the cysts, maximum cyst diameter, CEM, KEM, followup duration, or GFR at last visit between Groups 1 and
2 (Table 3). Besides, there was no significant correlation
between the GFR values at the last visit and the maximum
cyst diameter (r = –0.236, P = 0.187), CEM (r = –0.225, P
= 0.231), KEM (r = 0.193, P = 0.377) or follow-up duration
(r = –0.018, P = 0.923).
4. Discussion
Autosomal dominant polycystic kidney disease is the most
common monogenic renal disorder causing renal failure all
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over the world [1,2,5]. Although end-stage kidney disease
is expected in the sixth decade and it is controversial to
diagnose at-risk children, patients diagnosed with ADPKD
in childhood are becoming more common. In this study,
we reviewed our 41 patients with ADPKD diagnosed in
childhood. Five of them were diagnosed in the first 18
months of their lives, so called “VEO” ADPKD with two
being diagnosed in utero.
In ADPKD, clinical manifestations range from severe
neonatal presentation to renal cysts found by chance in the
childhood period [2]. Why some ADPKD cases present
in childhood is unknown and the type of mutation was
thought to be the underlying factor. It is well-known that
patients with a truncating mutation are more severely
affected [2]. Children diagnosed as VEO ADPKD also
represent a high-risk group. They are known to have more
HT and progression to chronic kidney disease (CKD) at a
median age of 16 years [2]. Five of our patients (12%) were
diagnosed with VEO ADPKD. Mothers of all five children
were also diagnosed with ADPKD and one also had a sister
with the disease. Two of them had an antenatal diagnosis
due to cysts determined in utero. Of the latter two cases,
five and four other relatives except their mothers were
diagnosed with ADPKD, respectively. Both had bilateral
multiple cysts with the largest diameter of >10 mm in the
antenatal and early postnatal periods. The first case had
a nonsense mutation resulting in a stop codon, while the
other case had a missense mutation.
The genes responsible for ADPKD are PKD1 or PKD2,
encoding polycystin-1 (PC1) and -2 (PC2), and accounting
for 85 and 15% of the patients, respectively [1,2]. Recently,
a third gene, namely GANAB (glucosidase, alpha, neutral
AB form), has been identified to cause ADPKD [2]. Most
cases are familial, however, family history is lacking in
10%–25% of patients including de novo disease in up to
10%–15% [6]. In our series, all the cases had a maternal
or paternal history of ADPKD and none had a de novo
condition at all. Twenty-five patients had PKD1 and
only 1 patient had PKD2 mutation. Unfortunately, PKD1
mutations are known to be associated with a more severe
disease course and progress to end-stage renal disease 20
years earlier than those with PKD2 mutations and those
with the latter mutation have fewer renal cysts [1]. It is
hard to comment on this topic with only one patient with
PKD2 mutation, however, our patient had a relatively low
number of cysts. In two of our patients, no identifiable
mutation was found, although they all had bilateral cysts
and positive family history, and one additionally had VEO
ADPKD. We may speculate that they had mutations that
had not been identified yet or they may have mutations
in GANAB, which cannot be checked in the genetic
laboratory that we used to work with.
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Table 2. Characterization of patients with very early onset ADPKD.
Sex

Time the first cyst
determined (month)

Family history

Mutation

P6

F

17

Mother, siblings

p.Asp3451Asn(c.10351G>A)*

P11

M

AN

Father

No mutation in PKD1, PKD2 or PKDH1

P24

F

AN

Mother

p.Glu3518X (c.10552 G>T) **

P27

M

AN

Mother

p.Arg4154Cys (c.12460 C>T)*

P29

M

6,5

Mother

ND

AN: antenatal, ND: not determined, *: missense mutation, **: nonsense stop codon mutation.
Table 3. Demographic, radiological and clinical differences due to age at admission.
< 10y at admission (n = 30)

≥ 10y at admission (n = 11)

P

Sex (female)

17 (57%)

6 (55%)

0.961

Laterality (bilateral)

25 (83%)

10 (91%)

1.000

Max. cyst diameter at first admission (mm)

12.76 ± 5.49 (2–20)

18.09 ± 14.51 (10–60)

0.174

Max. cyst enlargement rate (mm/month)

0.11 (0.35–0.19)

0.33 (0.16–0.47)

0.082

Max. kidney enlargement rate (mm/month)

0.31 (0.24–0.38)

0.39 (0.25–0.44)

0.522

Follow-up duration (months)

61 (35–82.5)

24 (18.5–64.5)

0.176

GFR at last visit (mL/min/1.73m )

125.61 ± 23.32 (89.83–171.87)

131.22 ± 18.04 (100–172)

0.808

GHF at last visit

9 (31%)

2 (18%)

0.457

2

GFR: glomerular filtration rate, GHF: glomerular hyperfiltration.

A consensus for the diagnosis, screening, treatment,
or clinical care of children with ADPKD has been lacking
until recently [2]. Diagnosing ADPKD is still challenging
in children <15 years due to the lack of definitive criteria.
Although not validated, a child with positive family history
and a single cyst preferably >1 cm is generally assumed
to have ADPKD [2]. Genetic analysis may also complete
the diagnosis in a suspicious case, however may result in
negative, as seen in our two cases. Recently, a new clinical
practice guideline has been published on monitoring
children with ADPKD [7].
Screening is generally not recommended in
presymptomatic children due to insurability and emotional
problems [8,9]. Diagnosing a child may cause difficulties
in obtaining insurance in some countries. In addition, it
has been demonstrated that 22% of the parents have fallen
into depression and 62% feel guilty about their children’s
disease [9]. In Kidney Disease Improving Global Outcomes
(KDIGO) consensus guideline, screening presymptomatic
children at risk with ultrasound or genetic testing is not
recommended [10]. However, 3 different options for
parents have been offered: not to screen; to screen as young
as possible and disclose the results only to the parents, or

to screen and disclose the results to the whole family [10].
In the European ADPKD Forum, genetic analysis has been
defined as vital for diagnosis in children, but screening for
at-risk children has not been discussed [2]. In the recent
clinical guideline, discussing the potential harms and
benefits of being diagnosed with the family and the child if
possible, has been recommended [7]. In our series, patients
were mostly brought to our clinic by their parents to learn
whether the child has the disease, while in 19% of them,
cysts were defined in their ultrasound coincidentally.
However, family history was defined in almost all children
when asked or cysts were demonstrated in the ultrasound
(US) of their parents.
No definite treatment has been established for
children with ADPKD yet. That is another reason for
ADPKD to be controversial to screen. Tolvaptan, statins,
angiotension converting enzyme inhibitors (ACEIs), and
mTOR inhibitors may be used in adults. Currently, V2receptor antagonist tolvaptan is the only drug available
for selected adults (<50 years, CKD stages 1-3a, rapidly
progressing disease) to slow the progression of cyst
development and renal insufficiency [11]. There is no
enough evidence to use tolvaptan in children routinely,
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however, it has been used in a case with severe neonatal
ADPKD [12]. The results of an ongoing phase IIIb doubleblind, placebo-controlled study for tolvaptan treatment
in children with ADPKD aged 4–17 years is pending
[13]. Another treatment of choice in pediatric ADPKD
is statins. In a 3-year randomized, double-blind, placebocontrolled study in children with ADPKD aged 8–22
years demonstrated that pravastatin may slow down the
progression of kidney disease [14]. However, statin use in
that age group is not safely advisable. A 5-year study on the
effects of ACEIs in patients with ADPKD aged 4–21 years
could not demonstrate any benefit on renal growth [15].
Due to the side effects and disappointing results in adults,
mTOR inhibitors have no place for treatment in children
with ADPKD as well [16]. Thus, none of our patients were
on routine treatment.
It is well-known that disease progression can be
prevented by modifiable factors including proteinuria
and hypertension [2,16]. In a metaanalysis, Marlais et al.
have found that 20% of children with ADPKD have HT
[17). They have observed that many children with ADPKD
are not under regular follow-up and have recommended
regular blood pressure control for all children at risk for
ADPKD [17]. In KDIGO, it is recommended to screen
children with a family history of ADPKD for HT from the
age of 5 years and to repeat blood pressure measurements
at 3 year intervals in case the patient is normotensive [10].
In the recent clinical guideline, blood pressure monitoring
at least once every 2 years has been recommended for
children aged 5 years and above and diagnosed with
ADPKD or those at risk for developing the disease [7].
Target blood pressure limits have not been established
well for children with ADPKD. In KDIGO, a goal blood
pressure <90th percentile for age, sex, and height with
renin-angiotensin-aldosteron system blockade as first-line
treatment has been offered [10]. However, in a more recent
study, a goal blood pressure ≤50th percentile with ACEIs
has been reported to correlate with better eGFR and left
ventricular mass index levels [14]. In addition to HT and
proteinuria, glomerular hyperfiltration (GFH) is also a
bad prognostic factor associated with a significantly faster
renal function impairment and a higher renal growth rate
[18]. Only 1 of our patients had HT and was put on ACEI,
and 6 had orthostatic proteinuria. 26% of our patients had
GHF and fortunately, none had a GFR lower than 90 mg/
mL/1.73m2 during the follow-up period. Other nephrourological problems in ADPKD include hematuria, pyuria,
urinary tract infections, or nephrolithiasis [1]. Hematuria
was detected in 12%, pyuria was detected in 10%, UTIs
were detected in 14%, and urolithiasis was defined in 7%
of the patients in our series.
It is well-known that ADPKD is a systemic disorder
causing cyst formation in other organs, mostly in the liver
and pancreas, intracranial arterial aneurysms, cardiac
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valvular defects, inguinal and abdominal herniation, in
addition to nephro-urological problems. Only one of
our patients had hepatic cysts, and none had a splenic
or pancreatic cyst. Screening children for intracranial
aneurysms is uncertain. However, there is recent evidence
that screening all patients regardless of the family history
of aneurysms is cost-effective [19]. We have not routinely
searched for intracranial aneurysms, however, 5 of our
patients had MRA without any evidence of intracranial
aneurysms. Echocardiography was performed in 12 of the
patients that were normal in all but one with PFO.
Height-adjusted total kidney volume (TKV) has been
proven to be a strong and independent predictor for endstage renal disease (ESRD) development in ADPDK [2].
We could not measure TKV in our patients. Instead, we
have assessed the kidney sizes and cyst diameters obtained
by ultrasonography and changes in them throughout the
follow-up period. In adults, the total kidney and cyst
volume enlargement rate slow down with age. In children,
they are higher than adults and highest during puberty [1].
However, we could not exactly define such a correlation
between the follow-up duration and cyst enlargement.
In addition, age at diagnosis has no influence on cyst or
kidney enlargement during the follow-up.
The results of our study should be interpreted with its
limitations. The first was the retrospective design of our
study and the second was the limited number of cases. As
recommendations for screening was unclear, not all our
patients had evaluation for intracranial aneurysms, which
is another limitation. Finally, not all the cases had genetic
analysis and this prevented a definitive analyses about the
correlations of mutations and the clinical entities.
5. Conclusion
The majority of children with ADPKD in this study
were found to have preserved renal functions and slight
cyst enlargement during their follow-up supporting the
debate about diagnosing children at-risk. However, early
precautions have the potential to delay progression to
ESRD and the patients may have different renal problems
deserving closed follow-up. It would be more valuable to
diagnose those children at-risk if ongoing trials define
effective treatment strategies for cyst enlargement.
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